logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9603926 B1

PDFFull Text
Date of Patent:
Mar. 28, 2017

Filed:

Aug. 07, 2014

Histone deacetylase (hdac) inhibitors for the treatment of cancer

Applicant:

Topotarget Uk Limited, Abingdon, Oxfordshire, GB;

Inventors:

Henri Lichenstein, Branford, CT (US);

Nicholas Edwards, Abingdon, GB;

James Ritchie, Abingdon, GB;

Kamille Dumong Erichsen, Copenhagen, DK;

Jane Plumb, Glasgow, GB;

Assignee:

TopoTarget UK Limited, , GB;

Attorney:

Lerner, David, Littenberg, Krumholz & Mentlik, LLP

Primary Examiner:

Karen Canella

Int. Cl.
CPC ...
A61K 31/16 (2006.01); A61K 31/18 (2006.01); A61K 31/015 (2006.01); A61K 31/63 (2006.01); A61K 31/136 (2006.01); A61K 39/395 (2006.01); A61K 31/10 (2006.01); A61K 31/196 (2006.01); A61K 31/475 (2006.01); A61K 31/573 (2006.01); A61K 31/65 (2006.01); A61K 45/06 (2006.01); A61K 31/185 (2006.01); A61K 31/69 (2006.01);
U.S. Cl.
CPC ...
A61K 39/3955 (2013.01); A61K 31/10 (2013.01); A61K 31/185 (2013.01); A61K 31/196 (2013.01); A61K 31/475 (2013.01); A61K 31/573 (2013.01); A61K 31/65 (2013.01); A61K 31/69 (2013.01); A61K 45/06 (2013.01);
Abstract

The present invention relates generally to methods for treating cancer. In one respect, the present invention relates to a method of treating a hematological cancer (e.g., multiple myeloma, leukemia, lymphoma) comprising administering to a patient in need thereof a therapeutically effective amount of a histone deacetylase inhibitor, for example, a histone deacetylase (HDAC) inhibitor as described herein, for example, PXD-101. In another respect, the present invention relates to a method of treating cancer (e.g., solid tumour cancer, e.g., rectal cancer, colon cancer, ovarian cancer, hematological cancer, e.g., multiple myeloma, leukemia, lymphoma) comprising administering to a patient in need thereof, a first amount of a histone deacetylase (HDAC) inhibitor, for example, a histone deacetylase inhibitor as described herein, for example, PXD-101, and a second amount of another chemotherapeutic agent, for example, another chemotherapeutic agent selected from: an antibody against VEGF, AVASTIN® (bevacizumab), an antibody against CD20, rituximab, bortezomib, thalidomide, dexamethasone, vincristine, doxorubicin, and melphalan, wherein the first and second amounts together comprise a therapeutically effective amount.

Find Patent Forward Citations

Loading…